Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany

In Germany, ~8 million patients take angiotensin receptor blockers (ARBs) and 2.25 million of them valsartan. In 2018, contamination of generic ARBs with probable carcinogenic nitrosamines resulted in more than 30 recalls. The impact of such a huge recall has never been explored in Europe. We analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudolph, Ulrike Maria, Enners, Salka, Kieble, Marita, Mahfoud, Felix, Böhm, Michael, Laufs, Ulrich, Schulz, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502678/
https://www.ncbi.nlm.nih.gov/pubmed/33057175
http://dx.doi.org/10.1038/s41371-020-00425-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502678/
https://www.ncbi.nlm.nih.gov/pubmed/33057175
http://dx.doi.org/10.1038/s41371-020-00425-z

Ejemplares similares